AU2707797A - Methods and means for inhibition of cdk4 activity - Google Patents

Methods and means for inhibition of cdk4 activity

Info

Publication number
AU2707797A
AU2707797A AU27077/97A AU2707797A AU2707797A AU 2707797 A AU2707797 A AU 2707797A AU 27077/97 A AU27077/97 A AU 27077/97A AU 2707797 A AU2707797 A AU 2707797A AU 2707797 A AU2707797 A AU 2707797A
Authority
AU
Australia
Prior art keywords
cdk4
activity
inhibition
methods
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27077/97A
Other languages
English (en)
Inventor
Kathryn Lindsay Ball
David Philip Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed by University of Dundee filed Critical University of Dundee
Publication of AU2707797A publication Critical patent/AU2707797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU27077/97A 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity Abandoned AU2707797A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GB9609521 1996-05-08
GB9621314 1996-10-09
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use
PCT/GB1997/001250 WO1997042222A1 (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Publications (1)

Publication Number Publication Date
AU2707797A true AU2707797A (en) 1997-11-26

Family

ID=26309279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27077/97A Abandoned AU2707797A (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Country Status (7)

Country Link
US (3) US6962792B1 (enExample)
EP (1) EP0898580B9 (enExample)
JP (1) JP4205165B2 (enExample)
AT (1) ATE333465T1 (enExample)
AU (1) AU2707797A (enExample)
DE (2) DE69736351T4 (enExample)
WO (1) WO1997042222A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736351T4 (de) 1996-05-08 2009-07-23 Cyclacel Ltd. Methoden und mittel zur hemmung der cdk4-aktivität
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
CA2321467A1 (en) * 1998-02-18 1999-08-26 Theryte Limited Treating cancer
BR9907965A (pt) * 1998-03-23 2000-12-12 Du Pont Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
EP1140202A1 (en) * 1998-12-24 2001-10-10 Ucb S.A. Peptidic product, process and composition
CA2367385A1 (en) * 1999-04-07 2000-10-12 E.I. Du Pont De Nemours And Company Cell cycle in plants
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
WO2004015071A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
US20080026992A1 (en) * 2003-10-20 2008-01-31 Ludger Hengst Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
BRPI0415759A (pt) * 2003-10-21 2006-12-19 Cyclacel Ltd compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CA2576159A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
EP1909811B1 (en) * 2005-06-29 2012-02-01 St. George's Enterprises Limited Hox peptides as pbx modulators for the treatment of cancer
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
DE69333043T2 (de) 1992-10-16 2004-05-06 Cold Spring Harbor Laboratory Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
ATE283355T1 (de) 1994-05-24 2004-12-15 Baylor College Medicine Mimetika von aus alternden zellen abgeleitete hemmer der dna synthese
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
EP0850066A1 (en) 1995-07-20 1998-07-01 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
DE69736351T4 (de) 1996-05-08 2009-07-23 Cyclacel Ltd. Methoden und mittel zur hemmung der cdk4-aktivität

Also Published As

Publication number Publication date
JP4205165B2 (ja) 2009-01-07
EP0898580B9 (en) 2009-08-12
DE69736351D1 (de) 2006-08-31
EP0898580A1 (en) 1999-03-03
EP0898580B3 (en) 2008-10-29
US6962792B1 (en) 2005-11-08
DE69736351T4 (de) 2009-07-23
US20040214765A1 (en) 2004-10-28
EP0898580B1 (en) 2006-07-19
DE69736351T2 (de) 2007-07-12
ATE333465T1 (de) 2006-08-15
WO1997042222A1 (en) 1997-11-13
JP2000513805A (ja) 2000-10-17
US20080249025A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
DE69736351D1 (de) Methoden und mittel zur hemmung der cdk4-aktivität
Kulikov et al. Mdm2 facilitates the association of p53 with the proteasome
Mei et al. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2
AU3738397A (en) 2-methoxyestradiol-induced apoptosis in cancer cells
AU3847997A (en) Inhibitors of the interaction between P53 and MDM2
IL117425A0 (en) Receptor activation by gas6
AU1367095A (en) Effector proteins of rapamycin
WO2001031335A3 (en) Cell proliferation diagnosis and screening for modulators
WO1999006540A3 (en) Inhibitors of cell-cycle progression and uses related thereto
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
WO1996034113A3 (en) Methods for the identification of farnesyltransferase inhibitors
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
CA2273080A1 (fr) Mutants de la proteine lag-3, leur expression et utilisation
WO2004069200A3 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
MXPA01010588A (es) Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk.
AU749763C (en) Modification of cereal grain hardness via expression of puroindoline proteins
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
AU6865600A (en) Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same
AU7216498A (en) Inhibitors of the urokinase receptor
AU1559501A (en) Apoptosis inducing proteinaceous substance
WO2004075839A3 (en) Methods and compositions for modulating apoptosis
Nikolaev et al. PARC: a potential target for cancer therapy
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität